Back
ESC Professional Premium Access

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

Session: What's new in lipid lowering?
Topic: Drug therapy
Speaker: Doctor A. Khera (Boston, US)
Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)
0 follower

5 more presentations in this session

Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 59 trials

Speaker: Doctor P. Burger (Utrecht, NL)

Access
Abstract
Slides
Video
Thumbnail

Attainment of LDL-cholesterol goals in patients with previous myocardial infarction: a real-world cross-sectional analysis

Speaker: Mr D. Gomes (Lisbon, PT)

Access
Abstract
Slides
Video
Thumbnail

Lipoprotein(a) is not a causal factor for the development of diabetes - a two-sample Mendelian randomization study.

Speaker: Associate Professor T. Osadnik (Zabrze, PL)

Access
Abstract
Slides
Video
Thumbnail

Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): Implications for the OCEAN(a)-Outcomes trial population

Speaker: Doctor B. Weber (Boston, US)

Access
Abstract
Slides
Video
Thumbnail

Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT

Speaker: Doctor P. Burger (Utrecht, NL)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

What's new in lipid lowering?

Speakers: Doctor A. Khera, Doctor P. Burger, Mr D. Gomes, Associate Professor T. Osadnik, Doctor B. Weber...
Access
Video
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb